Literature DB >> 7489237

Apolipoprotein A-I deficiency. Biochemical and metabolic characteristics.

D S Ng1, C Vezina, T S Wolever, A Kuksis, R A Hegele, P W Connelly.   

Abstract

Familial HDL deficiencies are associated with variable susceptibility to premature coronary heart disease, but the mechanism underlying this association remains poorly understood. Three homozygotes with isolated complete apo A-I deficiency caused by an autosomal codominant apo A-I Q[-2]X mutation and one heterozygote developed coronary heart disease before age 40 years. We characterized the effects of this mutation on lipoprotein metabolism. LDL FC, phospholipid, and apo B were all significantly higher in homozygotes than in heterozygotes. The HDLs of the heterozygotes were apo A-I poor relative to apo A-II. Lecithin-cholesterol acyltransferase activity was 59% lower in homozygotes than in normal subjects or heterozygotes. Cholesteryl ester transfer activity was increased in a homozygote compared with a normolipidemic control subject. Postprandial lipid metabolism was studied in one homozygote and one heterozygote. Post-prandial TG response in the homozygote was significantly exaggerated, while residual plasma HDL level remained unaffected. The homozygote also had delayed clearance of retinyl ester, a marker of chylomicron remnant metabolism. Thus, homozygosity and heterozygosity for apo A-I Q[-2]X are associated with qualitative, as well as quantitative, disturbances in plasma HDLs, LDLs, lipid-modifying enzyme activities, and postprandial retinyl ester metabolism. The observed elevation of atherogenic lipoproteins and reduction in antiatherogenic lipoproteins in the affected members of the apo A-I Q[-2]X kindred are consistent with the primary deficiency in apo A-I having pleiotropic effects that markedly enhance susceptibility for coronary heart disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489237     DOI: 10.1161/01.atv.15.12.2157

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

1.  Delayed loss of cholesterol from a localized lipoprotein depot in apolipoprotein A-I-deficient mice.

Authors:  O Stein; Y Dabach; G Hollander; M Ben-Naim; G Halperin; J L Breslow; Y Stein
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

Review 2.  HDL--is it too big to fail?

Authors:  Dominic S Ng; Norman C W Wong; Robert A Hegele
Journal:  Nat Rev Endocrinol       Date:  2013-01-15       Impact factor: 43.330

Review 3.  Human genetics of variation in high-density lipoprotein cholesterol.

Authors:  Atif Qasim; Daniel J Rader
Journal:  Curr Atheroscler Rep       Date:  2006-05       Impact factor: 5.113

4.  Apolipoprotein A-I, elevated in trauma patients, inhibits platelet activation and decreases clot strength.

Authors:  Wilbert L Jones; Christopher R Ramos; Anirban Banerjee; Ernest E Moore; Kirk C Hansen; Julia R Coleman; Marguerite Kelher; Keith B Neeves; Christopher C Silliman; Jorge Di Paola; Brian Branchford
Journal:  Platelets       Date:  2022-06-05       Impact factor: 4.236

5.  Swapping the N- and C-terminal domains of human apolipoprotein E3 and AI reveals insights into their structure/activity relationship.

Authors:  Mark T Lek; Siobanth Cruz; Nnejiuwa U Ibe; Wendy H J Beck; John K Bielicki; Paul M M Weers; Vasanthy Narayanaswami
Journal:  PLoS One       Date:  2017-06-23       Impact factor: 3.240

6.  Oxidizability assay of unfractionated plasma of patients' with different plasma profile: a methodological study.

Authors:  Hasan Imam; Arfia Chowdhury; Nasir Uddin Mahbub; Amir Hossain; Mohammed Faisal Bin Karim; Mohammad Burhan Uddin; Md Moklesur Rahman Sarker
Journal:  J Diabetes Metab Disord       Date:  2014-05-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.